[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Zetola-Burneo N, Brown C: Cases from the Osler Medical Service at Johns Hopkins University. Am J Med; 2004 Feb 1;116(3):198-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 47-year-old white woman with a history of stage III squamous cell carcinoma of the anus was transferred to Johns Hopkins Hospital for further evaluation of renal failure, hemolytic anemia, and thrombocytopenia.
  • The patient was first diagnosed with squamous cell carcinoma of the anus 1 year before admission.
  • One month before admission, she underwent a cystoscopy, which showed only radiation-induced changes in the bladder.
  • Laboratory data showed a white blood cell count of 6390/mm(3), a hematocrit level of 26.5%, and a platelet count of 26,000/mm(3).
  • There was no radiographic or clinical evidence of relapse of her squamous cell carcinoma.
  • [MeSH-minor] Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14749166.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


2. Stokes Z, Symonds P, Habeshaw T, Reed N, Curto J, Joynson C, Chan S: Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer. Gynecol Oncol; 2005 Jun;97(3):790-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer.
  • OBJECTIVE: A dose escalation study was performed for patients with locally advanced squamous carcinoma of cervix to determine the maximum tolerated dose (MTD) of daily capecitabine when combined with weekly cisplatin and radiotherapy.
  • MTD would be reached if at least 2 out of 6 at any particular dose level developed Grade 3 or 4 diarrhoea, mucositis, skin or bladder toxicity or Grade 4 neutropenia associated with fever lasting more than 7 days or Grade 3 or 4 thrombocytopenia.
  • METHODS: Thirteen patients were enrolled (7 Stage II(b), 6 Stage III(b)).
  • Three patients have developed late (RTOG/ECOG) Grade 3 toxicity bladder or vaginal mucosa at 6, 9 and 15 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Deoxycytidine / analogs & derivatives. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Capecitabine. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / analogs & derivatives. Hematologic Diseases / chemically induced. Hematologic Diseases / etiology. Humans. Middle Aged. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894361.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Chen Y, Xu H, Li Y, Wang D, Li J, Yuan J, Liang Z: The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients. Ann Surg Oncol; 2008 Oct;15(10):2847-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of laparoscopic radical hysterectomy and lymphadenectomy for cervical cancer: a prospective analysis of 295 patients.
  • OBJECTIVES: Cervical carcinoma is likely to become one of the most important indications for laparoscopic radical surgery.
  • The laparoscopic technique combines the benefits of a minimally invasive approach with established surgical principles.
  • In our institution, the laparoscopic radical hysterectomy and transperitoneal approach for lymphadenectomy have become the standard techniques for invasive cervical cancer.
  • METHODS: Between February 2001 and June 2007 we performed laparoscopic radical hysterectomies for cervical cancer in 295 patients.
  • Other medical problems included 47 cases (15.9%) of bladder dysfunction and 62 cases (21.0%) of rectum dysfunction or constipation.
  • CONCLUSION: Laparoscopic radical hysterectomy is a routine, effective treatment for patients with Ia2-IIb cervical carcinoma.
  • With more experience it is envisaged that IIb stage patients can be managed safely offering all the benefits of minimal surgery to the patients.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / pathology. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome


Advertisement
4. Shimabukuro T, Nakamura K, Uchiyama K, Tei Y, Aoki A, Naito K: Angiotensin-II combined intra-arterial chemotherapy for locally advanced bladder cancer: a case series study at a single institution. Hinyokika Kiyo; 2006 Feb;52(2):99-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiotensin-II combined intra-arterial chemotherapy for locally advanced bladder cancer: a case series study at a single institution.
  • Patients with locally advanced bladder cancer are at significant risk for metastases.
  • The possibility of bladder preservation is also discussed.
  • Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4NxM0).
  • Our results suggest that intra-arterial chemotherapy combined with AT-II is a useful treatment for patients with locally advanced bladder cancer, since this modality achieves a favorable response rate without severe toxicity or mortality.
  • [MeSH-major] Angiotensin II / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Administration Schedule. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541762.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11128-99-7 / Angiotensin II; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement